COMPANY PROFILE

Dr. Noah Biotech

Explore full profile

Innovative drug combinations for orphan diseases using advanced bioinformatics and machine learning

Suwon, South KoreaFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Dr. Noah Biotech

Dr. Noah Biotech specializes in developing innovative drug combinations for orphan diseases, leveraging advanced bioinformatics and machine learning technologies. The company operates in the biopharmaceutical sector, targeting a niche market of patients with rare diseases that often lack sufficient treatment options. Dr. Noah Biotech's business model revolves around its proprietary Multi Strategy Drug Repositioning System, which identifies synergistic drug partners to enhance therapeutic efficacy and reduce toxicity. Revenue is generated through partnerships with pharmaceutical companies, research grants, and licensing agreements. The company serves a global clientele, including pharmaceutical firms, research institutions, and healthcare providers, aiming to improve patient outcomes through cutting-edge drug discovery and development.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Suwon, South Korea
Employees: 14
Open positions: None listed
Dealroom signal: 22.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jun 2022	$18M	$72M	CKD Venture Capital Corporation · L&S Venture Capital	—
SERIES AEquity / VC	Aug 2020	$0	—	BNH Investment · T-Investment	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Dr. Noah Biotech website traffic

Latest recorded traffic for Dr. Noah Biotech is 1.7K monthly website visits, up 13.3% over the last three months. Dr. Noah Biotech's team declined 17.6% over the past year.

Latest monthly visits1.7K 3-month web change+13.3% 1-year team growth-17.6%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BABasgenbioVaszenio is a bio-vitator based on artificial intelligence that offers more than health value	Seoul, South Korea	Operational	20	$13M	$34M
PHPharosiBioAI platform-based rarest-equivalent disease, a drug-developing company	Anyang-si, South Korea	Operational
CTCongruence TherapeuticsBuilding the leading pharmacological stabilizer company for the treatment of rare diseases	Montreal, Canada	Operational
ACAceragenDeveloper of therapeutic treatments intended for rare and ultra-rare diseases	Durham, United States	Acquired
NENetTargetsAI-enhanced systems biology platform for drug discovery	Daejeon, South Korea	Operational
PBPath BioAnalyticsAn Advanced assays accelerating the discovery, development and use of new medications for respiratory disease	Chapel Hill, United States	Operational
FBForge BiologicsA gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality	Columbus, United States	Acquired
SASaventicAI-powered platform supporting rare disease diagnosis	Toruń, Poland	Operational